Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

Authors:

Abstract
No abstract available
Funding Information
  • US Department of Health and Human Services
  • NIH
  • NIH/NCI
  • TCGA (U24 CA143866)
  • NIH/NCI (HHSN 261201000021l, HHSN261201000032I)
  • TCGA Project
  • NIH/NCI (HHSN261200800001E)
  • NIH/NCI (U24 CA143883)
  • NIH/NCI (U24 CA143867)
  • NIH/NCI (U24CA210950, U24CA209851, U01CA168394)
  • NIH/NCI U24 (CA199461, CA210949, CA210950)
  • NIH/NCI (P50 CA100632)
  • NIH/NCI (4UL1 TR000371)
  • NIH/NCI (U24 CA143882)
  • NIH/NCI (P50 CA91846)
  • NCI CCSG (P30 CA016672)
  • MD Anderson’s Sequencing and Microarray Facility
  • NIH/NCI (P30 CA008748)
  • NIH/NCI (P30 CA016672)
  • Bioinformatics Shared Resources
  • NIH intramural research program project (Z1AES103266)
  • NIH/NCI (1P01CA120964)
  • NIH/NCI (R01CA178744)
  • NIH/NCI (R01CA155010)
  • NCI (PAR-16-025)
  • DoD Lung Cancer Development (LC150174)
  • Partnership for Bladder Cancer Research, Scott Department of Urology, Baylor College of Medicine
  • Leukemia and Lymphoma Society Scholar Award
  • Mary K. Chapman Foundation (80-107216-19)
  • Michael and Susan Dell Foundation
  • National Research Council (CNPQ) of Brazil
  • Pró-Reitoria de Pesquisa
  • UNICAMP (FAEPEX 2885/16, FAEPEX 2803/16)
  • Federal Agency for Support and Evaluation of Graduate Education (CAPES) of Brazil
  • TCGA Network (U54 HG003273, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848, U24 CA143858, U24 CA144025)
  • AstraZeneca